RFXAP

Across TCGA pan-cancer cohorts, RFXAP mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RFXAP’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RFXAP mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RFXAP is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where RFXAP tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFXAP mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.347	<.001	7	view →
HNSC	All	II,III,IV	+0.186	.024	3	view →
LSCC	Female	All	−0.180	.006	3	view →
CCRCC	All	IV	+0.332	.014	2	view →
PDAC	All	III,IV	−0.516	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RFXAP–LUAD

Open the LUAD breakdown →